Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12275685

    Oligo-benzamide analogs and their use in cancer treatment

    The Board of Regents of the University of Texas System · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12263143

    Ionic channel modulation as a method for treating tumors through inflammasome activation

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12263165

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    The Board of Regents of the University of Texas System · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2025062334

    DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER

    BEIGENE SWITZERLAND GMBH [CH] · Granted Thu Mar 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12257278

    Methods of treating cancer with TNF expressing myxoma virus

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12252493

    Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer

    Mirati Therapeutics, Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12247973

    Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

    UNIVERSITÄTSKLINIKUM REGENSBURG · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2025040080

    TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE

    BEIGENE SWITZERLAND GMBH [CH] · Granted Thu Feb 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12233075

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12233087

    Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions

    The United States Government represented byt The United States Department of Veterans Affairs · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12233135

    Therapeutic constructs for treating cancer

    PRECISION MOLECULAR INC. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12234516

    Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof

    The Board of Regents of the University of Texas System · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12233073

    Skin care formulations and skin cancer treatment

    Regents of the University of Minnesota · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12233129

    Methods and compositions for the treatment of cancer

    SOUTH DAKOTA BOARD OF REGENTS · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12227763

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12227482

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12220420

    Combination therapy for cancer treatment

    Galera Labs, LLC · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12221627

    Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12220415

    WEE1 kinase inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12213977

    Methods and compositions for treating melanoma

    The Regents of the University of California · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12203098

    Cells having solid tumor targeting backbone and use thereof

    Fate Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12195804

    Treatment of squamous cell carcinoma

    The Board of Regents of the University of Texas System · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12195447

    Azolopyrimidine for the treatment of cancer-related disorders

    Arcus Biosciences, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12195766

    Tumor-selective E1a and E1b mutants

    The Regents of the University of California · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12188048

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12188005

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12186428

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12187782

    PDL1 peptides for use in cancer vaccines

    IO Biotech ApS · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12187792

    IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12187992

    Method and device for early cancer screening

    The Regents of the University of California · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12186378

    Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12186342

    Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha

    The Regents of the University of California · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 2025002606

    Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

    BAVARIAN NORDIC AS [DK] · Granted Thu Jan 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Dec 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12178887

    NIR-conjugated tumor-specific antibodies and uses thereof

    The Regents of the University of California · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12180296

    Cross species single domain antibodies targeting mesothelin for treating solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12171765

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12171818

    Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12168054

    Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

    Syndax Pharmaceuticals, Inc. · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12162877

    Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation

    DRUG DISCOVERY AND CLINIC S.R.L. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12161724

    Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

    JANUX THERAPEUTICS, INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.